SXSW 2024

Man vs. Nature: The Commercialization of Psilocybin Medicine


Psilocybin has emerged as a promising therapy for a number of mental health conditions. Though it is produced naturally by various mushroom species, nearly all clinical studies use synthetic psilocybin. Do the alkaloids only present in fungal bodies augment psychoactive and therapeutic value? This panel will detail the current state of research in psilocybin, the differences between natural and synthetic psilocybin, discuss the potential harms of limiting research to synthetic mushrooms, and explain why researchers have been fighting to study natural drug products.

Related Media

Other Resources / Information


  1. Analyze the differences between natural psilocybe mushrooms and synthetic psilocybin, including the other bioactive compounds found in mushrooms
  2. Explain how the effects of these compounds on augmenting psilocybin psychoactivity or clinical benefits remain unknown and unstudied
  3. Understanding the role of these ancillary compounds, as well as how they may augment psilocybin’s effects, may lead to optimized psilocybin therapies



Shawn Hauser, Partner, Vicente LLP

Meta Information:

  • Event: SXSW
  • Format: Panel
  • Track: Psychedelics
  • Track 2
  • Level: Intermediate

Add Comments

comments powered by Disqus

SXSW reserves the right to restrict access to or availability of comments related to PanelPicker proposals that it considers objectionable.